A venture capital firm invests primarily in very early-stage companies, from pre-seed to seed stages. The firm’s average check size ranges from $250,000 to $500,000. While the firm is focused on the US, particularly in the West Coast, it remains open to global opportunities. The firm is flexible in both lending and co-investing and may seek an observer seat on a case-by-case basis. The firm plays an active role in supporting its portfolio companies, assisting them with concept validation, clinical trials, and navigating reimbursement and regulatory pathways. The firm also provides resources to help companies gather data and evidence for their minimum viable products.
The firm is interested in opportunities across digital therapeutics, diagnostics, and medical devices. Some key indication areas of interest include cardiovascular, metabolic, diabetes, nephropathy, and women’s health. The firm typically focuses on less traditional pharma products, such as compounds and cell-based therapies. The firm prefers to engage with companies at an early stage and will consider those with at least a minimum viable product.
The firm does not have specific requirements for a company’s founding team. However, the firm prefers companies based in the U.S. or those with incentives to relocate to the U.S.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment